Greater Manchester fish and chip shop named one of best in UK
The restaurant, which is in the heart of Bolton town centre, started from humble beginnings as a small takeaway run by owner Tasos Pattichis in 1988. As time went on, Pattichis, who moved to Bolton with his family from Greece as a young child, managed to buy neighbouring buildings on Great Moor Street and eventually turned Olympus into a mammoth 200-seater restaurant that has become a tourist attraction.
Olympus has also been a hit with locals, including famous presenter and comedian, Paddy McGuinness, who is known to be a big fan. Recently, the eatery was finally able to display their Blue Ribbon trophy which was in recognition of the chippy's food quality and service.
READ MORE: UK weather maps shows where snow will fall as Met Office warns of -7C freeze
READ MORE: The patch of land in Greater Manchester 'critical' for the country's future
Speaking about the award, Tasos, 65, told the MEN: "I feel as though we are a really good team and we've been established for 36 years. I have staff that have been working here for 25 years.
"What you get there is a family orientation out of it and the customers love it because they see the same staff. They've become attached and when they come here they are given a memorable experience, not just because the fish and chips are good quality but also the service, which I think is next to none.
"The England's Business Award was the biggest one. It's a little bit more prestigious and there was more to do with it, it involved secret shoppers and more that we had to go through.
"We go through a lot with all the awards but that one was on the next level."
The Blue Ribbon for Delicious Dishes is an award given by the Good Food Awards food businesses with high customer ratings and votes. Winners are chosen based on their food quality, service, and value.
Last year was the restaurant's 36th anniversary, a year which brought more success after Olympus was crowned as the Best Fish and Chip Shop in the Manchester category.
Speaking about the accolade, which was handed to the business during a show at the Mercure Manchester Piccadilly Hotel in July.
Tasos added: "I've been in this trade a long time and because I grew up in the industry and its a way of life myself, to see what I've experienced from a young age until now, I feel extremely proud.
"The pride comes from pleasing others, the customers, the staff. It is exciting for me all the time."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
Olympus, Revival Healthcare partner to start GI robotics firm
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Dive Brief: Olympus said Friday it is partnering with Revival Healthcare Capital to develop a robotic system initially focused on gastrointestinal treatments. Tokyo-based Olympus and Austin, Texas-based Revival have agreed to found Swan EndoSurgical and will jointly invest up to $458 million to develop the robotic platform. Revival said it is taking a majority equity stake in the startup, and the structured investment gives Olympus an option to acquire Swan. Medtech trade group AdvaMed said the unique deal between two of its members — co-founding a third company to develop a specific medical technology — will bolster medtech's already strong manufacturing and research and development presence in the U.S. Dive Insight: Gastroenterologists perform endoscopic procedures such as cancer resection by inserting instruments through a natural orifice, but manual endoscopes have limitations that make many advanced procedures within the GI tract challenging and not widely available globally, according to Olympus. Boston-based Swan, which also has a technology center in Cambridge, U.K., aims to develop an endoluminal robot with flexible arms for maneuvering within the GI tract to treat lesions or tumors. The goal is to offer patients safer and more effective treatment, with faster recovery times, according to Olympus. Bob White, the former president of Medtronic's medical surgical business who stepped into Olympus' CEO role on June 1, said the collaboration with Revival is expected to help reshape the GI market by expanding physicians' procedural capabilities. 'This will allow the delivery of transformative, organ-sparing care that enhances outcomes for a broad patient population,' White said in a statement. The technology also has the potential to be applied in other disease areas, Olympus said. Olympus will take a 'significant equity stake' in Swan with a combined initial investment of at least $65 million. Total combined funding could reach $458 million if pre-agreed milestones are met, according to the announcement. Revival, a medtech-focused investment firm that is also a backer of surgical robot company Distalmotion, said the deal gives Olympus an option to acquire Swan at a predetermined value, while Revival has protective rights if Olympus chooses not to exercise the option. In welcoming the formation of Swan, AdvaMed CEO Scott Whitaker said the new company will bring good jobs to the U.S. 'This is a good sign that the medtech ecosystem is getting stronger,' said Whitaker. Recommended Reading Olympus pledges prompt response following FDA import block
Associated Press
3 days ago
- Associated Press
Olympus Enters Strategic Partnership to Develop Endoluminal Gastrointestinal Robotics
Olympus Co-founds Swan EndoSurgical With Revival Healthcare Capital TOKYO - July 28, 2025 ( NEWMEDIAWIRE ) - Olympus Corporation (Olympus), a global MedTech company committed to making people's lives healthier, safer, and more fulfilling, today announced the conclusion of an agreement with Revival Healthcare Capital (Revival) to drive advancements in endoluminal robotics. Olympus and Revival will co-found Swan EndoSurgical, a new company dedicated to developing a novel robotic system designed to revolutionize gastrointestinal (GI) patient care in the future. Endoluminal robotics aims to empower more physicians to safely perform innovative techniques, enhancing patient access to treatment options that support safety and improved recovery times. This groundbreaking advancement has the potential to create new and significantly enhanced minimally invasive treatment options for major unmet medical needs by boosting precision and efficiency in procedures addressing ergonomic strain for healthcare professionals. Bob White, Representative Executive Officer, President and Chief Executive Officer at Olympus, commented, 'This partnership marks a significant milestone in our strategic initiative to advance endoluminal robotics. We are excited to enter this collaboration that we expect to play a pivotal role in reshaping the GI market by expanding procedural capabilities for physicians. This will allow the delivery of transformative, organ-sparing care that enhances outcomes for a broad patient population.' For decades, endoscopy - placing a flexible camera into an existing body orifice - has yielded early and accurate diagnoses of conditions such as GI tract cancer. In recent years, specialists, primarily gastroenterologists, have begun performing endoscopic therapeutic procedures, such as cancer resection, by inserting instruments through the endoscope. However, manual endoscopes and their instruments have limitations that make many advanced procedures within the lumen of the GI tract challenging and not widely available globally. The development of an endoluminal robot, with its ability to easily maneuver within the GI tract and deploy flexible arms, provides the opportunity for more patients to benefit from safe and effective procedures, potentially avoiding invasive surgery. This innovation allows for the early, safe, and effective treatment of lesions or tumors in the GI tract relative to current therapeutic options. Furthermore, the technology has the potential for application in numerous other disease areas. Headquartered in the United States, Swan EndoSurgical has assembled a leadership team of highly experienced industry professionals who will drive technical, clinical, and commercial development of the robotic platform. About Swan EndoSurgical Swan EndoSurgical, Inc. is an innovative start-up co-founded by Revival Healthcare Capital and Olympus that is focused on the development of endoluminal surgical robotics with the aim to create effective treatment of lesions or tumors in the GI tract relative to current therapeutic options. For additional information, visit the Company's website at or contact [email protected]. About Revival Healthcare Capital Revival Healthcare Capital is an investment firm focused on the MedTech sector. Revival specializes in transformative external innovation partnerships and other opportunities where its team of experienced operators and investors believes it can provide leadership, resources, and deep sector insights - beyond its capital - to further support companies' growth strategies. For additional information, visit Revival's website at or contact [email protected] . About Olympus At Olympus, we are committed to Our Purpose of making people's lives healthier, safer, and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide innovative solutions and services for early detection, diagnosis, and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit and follow our global X account: @Olympus_Corp. Media contact: Mail: [email protected] Olympus Corp [TYO: 7733] [ADR: OLYMY] [STU: OLY1] [FRA: OLYS]
Yahoo
21-07-2025
- Yahoo
FluoGuide Enters Collaboration with Global MedTech Company Olympus
COPENHAGEN, DK / / July 21, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company"), a biotech company specializing in precision cancer surgery, announces a collaboration with Olympus, a global medical technology company. At FluoGuide, our mission is to help patients with cancer by improving precision surgery. Our lead product, FG001, has been clinically proven to light up cancer and guide surgeons in performing more precise surgeries. The objective of the collaboration is to develop FG001 for tumor imaging and surgical margins assessment for head and neck cancer. The focus of the current agreement is to support the clinical phase and to gather a body of evidence on Olympus's technology platforms used in combination with FG001. The agreement has no initial payment and is non-exclusive. The terms of this agreement are not disclosed, and the agreement will not have an impact on the Company's financial results in 2025. "The cooperation between Olympus and FluoGuide represents a substantial opportunity to contribute to the advancement of fluorescence and molecular imaging," says Simon Hirschfeld, Managing Director at Quest Medical Imaging, an Olympus Group Company. "Together, we look forward to shaping the future of research and innovation in this field and helping raise the standard of care for patients." "We're thrilled to partner with Olympus, a global leader in medical technology. This collaboration is an exciting step forward in advancing precision cancer surgery for head and neck cancer. By combining FluoGuide's FG001 technology with Olympus's imaging systems, we're working to improve surgical precision and deliver better outcomes for patients with cancer," says Morten Albrechtsen, CEO of FluoGuide. About OlympusAt Olympus, we are committed to Our Purpose of making people's lives healthier, safer and more fulfilling. As a global medical technology company, we partner with healthcare professionals to provide innovative solutions and services for early detection, diagnosis and minimally invasive treatment, aiming to improve patient outcomes by elevating the standard of care in targeted disease states. For more than 100 years, Olympus has pursued a goal of contributing to society by producing products designed with the purpose of delivering optimal outcomes for its customers around the world. For more information, visit and follow our LinkedIn account: Certified Adviser:Svensk Kapitalmarknadsgransking ABWebsite: For further information, please contact:Morten Albrechtsen, CEOFluoGuide A/SPhone: +45 24 25 62 66E-mail: ma@ About FluoGuideFluoGuide takes precision surgery to the next level improving the outcome for cancer patients. The Company's lead product, FG001, is designed to improve surgical precision by illuminating cancer intraoperatively. This improved precision enabled by FluoGuide's products is expected to have a dual benefit - it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, this improved precision will improve a patient's chance of achieving a complete cure and will lower systemwide healthcare costs. FG001 binds to the receptor uPAR being extensively expressed on most solid cancer types. The photothermal potential of FG001 could add a direct treatment effect of FG001 to further benefit for patients with cancer undergoing surgery. The Company has published strong results from phase II trials demonstrating the efficacy of FG001 as well as showing it was well tolerated and safe from clinical trials in patients undergoing surgery to remove aggressive brain (high-grade glioma), head & neck and lung cancers. Based on this strong foundation, FluoGuide expands the scope of application of FG001 and advances the development toward approval in aggressive brain cancer. FluoGuide is listed on Nasdaq First North Growth Market, Stockholm under the ticker "FLUO". Read more about FluoGuide's pipeline, technology, and upcoming events on This information is information that FluoGuide A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-07-21 13:46 CEST. AttachmentsFluoGuide enters collaboration with global MedTech company Olympus SOURCE: FluoGuide A/S View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
